SPECIAL-510(k) Submission for CAPNOSTREAM20 two parameter bedside monitor with microMediC02 G02 module
51 0(k) Summary of Safety and Effectiveness )u q (2
7. 510(k) Summary of Safety and Effectiveness yU t
This summary of safety and effectiveness information is being submitted in accordance with
the requirements of 21 CFR 807.92
(This section is not confidential) MAY k 2 2010
DATE THIS SUMMARY WAS PREPARED
December 15th ,2009
SUBMITTER'S NAME AND ESTABLISHMENT ADDRESS:
Oridion Capnography Inc.
160 Gould Street
Needham, MA 02494
ESTABLISHMENT REGISTRATION NUMBER
3003941644
CONTACT PERSON:
Rachel Weissbrod, Director of Regulatory Affairs
Oridion Medical 1987 Ltd.
Har Hotzvim Science Park
POB3 45025
91450 Jerusalem, Israel
Telephone: 857-9 19-2923
Fax: +972-2-586-6680
Email: rachel.weissbrod~oridion.com
DEVICE INFORMATION
Trade Name: Capnostream2o
Common Name: Two Parameter Bedside Monitor
Classification Name: Capnograph/Pulse Oximeter
Regulation Number:
868.1400, Carbon Dioxide Analyzer (Classification CCK)
870.2700 Pulse Oximeter (Classification DQA)
Device Listing Number: D001lliS.
Page 10SPECIAL-51 0(k) Submission for CAPNOSTREAM2O two parameter bedside monitor with microMediCO2 C02 module
510(k) Summary of Safety and Effectiveness
PREDICATE DEVICE
Capnostream20 with the microMediC02 002 board is substantially equivalent to the
following commercially available device:
Manufacturer Device 510(k)No. Clearance Date
Oridion 1987 Medical Ltd Capnostream20 K(082268 February gth, 2009
DEVICE DESCRIPTION
The Capnostream20 bedside monitor is a two parameter monitor consisting of a 002
capnography module and a pulse oximetry module implemented in a host device. The host
device displays parameters received from the respective modules and generates alarms
when preset alarm thresholds are crossed. The device is classified as CCK Class IL
according to 21 CFR ยง 868.1400 -Carbon Dioxide Analyzer with DQA 21 CFR ยง 870.2700
Pulse Oximeter listed as an additional or alternate classification.
This device has two modules that are classified as follows:
* 21 CFR 868.1400, Carbon Dioxide Analyzer (Classification CCK)
* 21 CFR 870.2700 Pulse Oximeter (Classification DQA)
Each module is controlled by dedicated software that is an integral part of the
respective module.
INTENDED USE
The Capnostream20 combined capnograph/pulse oximeter monitor is intended to provide
professionally trained health care providers the continuous, non invasive measurement and
monitoring of carbon dioxide concentration of the expired and inspired breath and
respiration rate, and for the continuous non-invasive monitoring of functional oxygen
saturation of arterial hemoglobin (SP02) and pulse rate. It is intended for use with neonatal,
pediatric and adult patients in hospitals, hospital type facilities, intra-hospital transport and
home environments.
The Capnostream20 monitor provides the clinician with an integrated pulmonary index (IPI).
The IPI is based on four parameters provided by the monitor: end tidal carbon dioxide,
respiration rate, oxygen saturation and pulse rate. The IPI is a single index of an adult or
pediatric patient's ventilatory status displayed on a scale of 1 -1 0, where 10 indicates
optimal pulmonary status. [Pi monitoring displays a single value that represents the
Page I11SPECIAL-51O(k) Submission for CAPNOSTREAM20 two parameter bedside monitor with microMediC02 002 module
510(k) Summary of Safety and Effectiveness
patient's pulmonary parameters and alerts clinicians to changes in the patient's pulmonary
status.
The IPI is an adjunct to, and is not intended to replace, vital sign monitoring
COMPARISON TO PREDICATE DEVICE
The Capnostream2O with the micromediCO2 C02 module is substantially equivalent to the
predicate Capnostream2O with the minimedi0O2 C02 module.
The new device meets the safety and performance standards met by the predicate device.
The functional features and the intended use of the Capnostream2O with the new C02
module are substantially equivalent to the predicate device. No significant changes were
made to the monitor hardware or software specifications to support the integration of the
new module. Slight mechanical changes were made to the monitor to accommodate the
smaller dimensions of the new module. The micromediCO2 module is smaller in size than
the miniMediC02 module, in order to facilitate integration inside other OEM monitors, and
provides enhanced processing and memory capacity, to support software applications for
future development. The module provides the following inputs to the host monitor:
FiCO2, EtCO2 numeric, EtCO2 waveform, Respiratory Rate, IPI (integrated Pulmonary
Index), and continuous 002 numeric and waveform.
The micromediCO2 includes a smaller lamp, a new solenoid, broader use of molded parts
to improve production quality, increased processing power, reduced power consumption
and improved flow regulation.
The module software provides full backward compatibility with the miniMedic02 and
supports RS232 or USB communication with the host monitor.
A hazard analysis was carried out on the module and on the Capnostream2O monitor with
the new module. This hazard analysis concluded that any residual risks were judged as
acceptable when weighed against the intended benefits of use of the system. Verification
and validation of the new module as a standalone and when integrated in the monitor were
successfully completed.
Page 12SPECIAL-510(k) Submission for CAPNOSTREAM20 two parameter bedside monitor with microMediC02 002 module
510(k) Summary of Safety and Effectiveness
Attribute Capnostream2O Bedside Predicate Device- Capnostream2O
Monitor with Bedside Monitor K082268
microMediCO2CO2 module
Indications for The indications for use are identical to The Capnostream2O combined
use the indications for use in the predicate capnograph/pulse oximeter monitor is intended
device to provide professionally trained health care
providers the continuous, non invasive
measurement and monitoring of carbon
dioxide concentration of the expired and
inspired breath and respiration rate, and for
the continuous non-invasive monitoring of
functional oxygen saturation of arterial
hemoglobin (SP02 and pulse rate). It is
intended for use with neonatal, pediatric and
adult patients in hospitals, hospital type
facilities, intra hospital transport and home
environments.
Target It is intended for use with neonatal, It is intended for use with neonatal, pediatric,
population pediatric, and adult patients. and adult patients.
Design Identical to the Capnostream2o See K082268
described in K082268 with the
exception of the introduction of the
micromediCa2 C02 module
Where Used It is to be used by physicians, nurses It is to be used by physicians, nurses and
and other trained health care other trained health care providers in critical
providers in critical care patient care patient settings, such as anesthesiology,
settings, such as anesthesiology, intensive care medicine, neonatal intensive
intensive care medicine, neonatal care and other health care areas.
intensive care and other health care
areas.
Performance ISO 21647 ISO 21647
Standards ISO 9919 ISO 9919
Safety IEC/EN 60601-1 lEO/EN 60601-1
Standards lEC/EN 60601-1-2 IEC/EN 60601-1-2
lEG 60601-1-8 lEC 60601-1-8
U L60601 -1 UL 60601-1
ISO 14971 ISO 14971
Biocompatibility There are no issues of There are no issues of biocompatibility for this
biocompatibility for this device and no device and no biocompatibility testing was
biocompatibility testing was done. done.
Sterility This device does not require This device does not require sterilization and is
sterilization and is shipped marked shipped marked non-sterile.
non-sterile.
Page 13SPECIAL-510(k) Submission for CAPNOSTREAM20 two parameter bedside monitor with microMediC02 C02 module
510(k) Summary of Safety and Effectiveness
CONCLUSION
Capnostream2O with the micromediCO2 C02 module does not raise any new potential
safety risks and is equivalent in performance to the existing legally marketed device.
Therefore, the device is substantially equivalent to the predicate device with respect to
safety, effectiveness, and intended use.
Page 14DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Food and Drug Administration
10903 Newv I ampshire Avenue
Documnent Control Roomn -W066-G609
Silver Spring, MD 20993-0002
Ms. Rachel WeissbrodMA12zo
Director of Regulatory Affairs
Oridion Capnography, Incorporated
160 Gould Street
Needham, Massachusetts 02494
Re: K0940121
Trade/Device Name: Capnostream20 with Micromnedico2 Module
Regulation Number: 21 CER 868.1400
Regulation Name: Carbon Dioxide Gas Analyzer
Regulatory Class: 11
Product Code: CCK
Dated: April 13, 201 0
Received: April 15, 201 0
Dear Ms. Weissbrod:
We have reviewed your Section 5 10(k) premnarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the
indications for use stated in the enclosure) to legally marketed predicate devices marketed in
interstate commerce prior to May 28, 1976, the enactment date of the Medical Device
Amendments, or to devices that have been reclassified in accordance with the provisions of
the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket
approval application (PMA). You may, therefore, market the device, subject to the general
controls provisions of the Act. The general controls provisions of the Act include
requirements for annual registration, listing of devices, good manufacturing practice,
labeling, and prohibitions against misbranding and adulteration. Please note: CDR-H does
not evaluate information related to contract liability warranties. We remind you, however,
that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class 11 (Special Controls) or class III
(PMA), it may be subject to additional controls. Existing major regulations affecting your
device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In
addition, FDA may publish further announcements concerning your device in the Federal
Register.Page 2- Ms. Rachel Weissbrod
Please be advised that FDA's issuance of a Substantial equivalence determination does not
mean that FDA has made a determination that your device complies with other requirements
of the Act or any Federal statutes and regulations administered by other Federal agencies.
You must comply with all the Act's requirements, including, but not limited to: registration
and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting
(reporting of medical device-related adverse events) (21 CFR 803); good manufacturing
practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);
and if applicable, the electronic product radiation control provis ions (Sections 53 1-542 of
the Act); 21 CFR 1000- 1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801),
please go to
http://www.fda.rz~ov/AboutFDA/CentersOffices/CDRH/CDRHOffices/uci II 5809.htm for
the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also,
please note the regulation entitled, "Misbranding by reference to premarket notification"
(2I CFR Part 807.97). For questions regarding the reporting of adverse events under the
MDR regulation (21 CFR Part 803), please go to
http://www.fda.gQov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH' s
Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other generaf information on your responsibilities under the Act from the
Division of Small Manufacturers, International and Consumer Assistance at its toll-free
numbe? (800) 638-2041 or (301) 796-71 00 or at its Internet address
http://www.fda.g2ov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Since rely yours,
Anthony D. Watson, B.S., M.S., M.B.A.
Director
Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
-Center for Devices and
Radiological Health
EnclosureSPECIAL-510(k) Submission for CAPNOSTREAM20 two parameter bedside monitor with microMediG02 G02 module
Statement of Indications for Use
6. Statement of Indications for Use
TWO PARAMETER CAPNOSTREAM MONITOR
(This document is not confidential)
Indications for Use
December 15th 2009
510(k) Number (if known) 1 0 + ~
Device Name: Capnostream 20
Indications far Use:
The Capnostream20 combined capnograph/pulse oximeter monitor is intended to provide
professionally trained health care providers the continuous, non invasive measurement and
monitoring of carbon dioxide concentration of the expired and inspired breath and respiration
rate, and for the continuous non-invasive monitoring of functional oxygen saturation of arterial
hemoglobin (SPO2) and pulse rate- It is intended for use with neonatal, pediatric and adult
patients in hospitals, hospital type facilities, intra hospital transport and home environments.
The Capnostreamn20 monitor provides the clinician with an integrated pulmonary index (IPI).
The IPI is based on four parameters provided by the monitor: end tidal carbon dioxide,
respiration rate, oxygen saturation and pulse rate. The IPI is a single index of an adult or
pediatric patient's ventilatory status displayed on a scale of 1 -10, where 10 indicates optimal
pulmonary status. IPI monitoring displays a single value that represents the patient's pulmonary
parameters and alerts clinicians to changes in the patient's pulmonary status.
The IPI is an adjunct to, and is not intended to replace, vital sign monitoring.
Prescription Use X AND/OR Over-The-Counter Use _ __
(Per 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE -CONTINUE ON ANOTHER PAGE IF
NEEDED)
(Division Sign-Oft)
Division of Anesthesiology, General Hospital
Infection Control, Dental Devices
510(k) Number: IzC G' I-
PageS9